el-Raghy I, Back D J, Osman F, Nafeh M A, Orme M L
Br J Clin Pharmacol. 1985 Oct;20(4):313-6. doi: 10.1111/j.1365-2125.1985.tb05069.x.
The pharmacokinetics of antipyrine have been studied in patients with schistosomiasis. In comparison to a control group of subjects (n = 6), patients with early (active) schistosomiasis (passing live ova in urine or stools without clinical and laboratory evidence of liver involvement; n = 6) exhibited similar pharmacokinetic parameters. Of seven patients with hepatosplenic schistosomiasis (exhibiting hepatic fibrosis, splenomegaly, at least one episode of haematemesis, ascites), five showed markedly enhanced antipyrine half-life and reduced clearance. Compared to controls, the mean half-life of this group was increased from 10.9 +/- 2.4 to 19.9 +/- 9.5 h (mean +/- s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/- 0.74 to 2.18 +/- 0.80 l h-1 (P less than or equal to 0.01). There was no change in the apparent volume of distribution. Liver biopsy was performed on all patients diagnosed as having hepatosplenic schistosomiasis in the 2 weeks prior to the antipyrine study. The results of this study indicate that hepatic microsomal metabolism is impaired in patients with advanced hepatosplenic schistosomiasis.
已对血吸虫病患者的安替比林药代动力学进行了研究。与对照组受试者（n = 6）相比，早期（活动期）血吸虫病患者（尿或粪便中排出活虫卵但无肝脏受累的临床及实验室证据；n = 6）表现出相似的药代动力学参数。在7例肝脾型血吸虫病患者（表现为肝纤维化、脾肿大、至少一次呕血、腹水）中，5例安替比林半衰期显著延长，清除率降低。与对照组相比，该组的平均半衰期从10.9±2.4小时增加到19.9±9.5小时（均值±标准差；P≤0.05），清除率从3.81±0.74升/小时降低到2.18±0.80升/小时（P≤0.01）。分布表观容积无变化。在安替比林研究前2周，对所有诊断为肝脾型血吸虫病的患者进行了肝活检。本研究结果表明，晚期肝脾型血吸虫病患者的肝微粒体代谢受损。
